**Supplementary Materials**

**Supplementary Acknowledgments:**

The KONNECTION study group included: Raphael Chiron, Hôpital Arnaud de Villeneuve, France; Kris De Boeck, universitaire Zeikenuizen, Belgium; Albert Faro, Washington University School of Medicine, United States; Jonathan Gaffin, Boston Children’s Hospital, United States; Peter Hiatt, Texas Children’s Hospital, United States; Susanna McColley, Ann & Robert H Lurie Children’s Hospital of Chicago, United States; John McNamara, Children’s Respiratory and Critical Care Specialists, P.A., United States; Anne Munck, Hôpital Robert Debré, France; Samya Nasr, University of Michigan Health System, United States; Philippe Reix, Hôpital Femme Mère Enfant, France; Mark Rolfe, New Lung Associates, United States; Seth Walker, Emory Cystic Fibrosis Center, United States.

**Figure S1.** Study design. q12h = dosed every 12 hours
Figure S2. Consolidated Standards of Reporting Trials (CONSORT) Diagram

- Screened: N = 42
- Randomized in Part 1
- Treatment Sequence 1: n = 20
- Completed: n = 18
- Treatment Sequence 2: n = 19
- Completed: n = 18
- Discontinued, n = 2
  - Reasons:
    - Lost to follow-up (n=1)
    - Other (n=1)
- Discontinued, n = 1
  - Reason:
    - Other
- Part 2
  - Open-label Extension
  - Rollover to Part 2: n = 18
  - Completed Part 2: n = 18

---

* Three patients failed screening: one patient had evidence of a lens opacity, and two had acute respiratory infection/pulmonary exacerbation/change in therapy in the 4 weeks prior to the first dose of study drug.

* One patient in treatment sequence 1 ('other') and one patient in treatment sequence 2 ('other') were discontinued because each required antibiotic treatment that extended the duration of the washout period in Part 1, resulting in a protocol violation.